Inicio>>Signaling Pathways>> GPCR/G protein>> Glucocorticoid Receptor>>Glucocorticoid receptor agonist-1

Glucocorticoid receptor agonist-1

Catalog No.GC62663

El agonista-1 del receptor de glucocorticoides es un potente agonista del receptor de glucocorticoides con una IC50 de 2,8 nM extraÍdo de la patente WO2017210471A1, compuesto 41.

Products are for research use only. Not for human use. We do not sell to patients.

Glucocorticoid receptor agonist-1 Chemical Structure

Cas No.: 2166375-82-0

Tamaño Precio Disponibilidad Cantidad
5 mg
594,00 $
Disponible
10 mg
990,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Glucocorticoid receptor agonist-1 is a potent glucocorticoid receptor agonist with an IC50 of 2.8 nM extracted from patent WO2017210471A1, compound 41[1].

Glucocorticoid receptor agonist immunoconjugates are useful for treating autoimmune diseases such as, but not limited to, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, pediatric Crohn’s disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, uveitis, Behcets disease, a spondyloarthropathy, or psoriasis[1].

[1]. Michael J. Mcpherson, et al. Glucocorticoid receptor agonist and immunoconjugates thereof. WO2017210471A1.

Reseñas

Review for Glucocorticoid receptor agonist-1

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Glucocorticoid receptor agonist-1

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.